Lisa LudwigEli Lilly (United States)1 paperORCID 0009-0001-1447-2717 ↗OpenAlex ↗PapersLancetHuman trial·1 OctCardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
LancetHuman trial·1 OctCardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial